Table 4.

Trends in Antimicrobial Susceptibility of All Tested Enterococci in Each Monitored Region for 1997–2016: SENTRY Program

			Susceptibility, %a
Region	Time Period	No. of Isolates	AMPb	CHLc	TETd	LZD	VAN
NA	1997–2000	4195	79.2	82.3	37.1	96.6	87.6
NA	2001–2004	3685	75.7	88.2	38.2	99.5	82.7
NA	2005–2008	6509	68.2	89.7	37.8	99.2	72.5
NA	2009–2012	6130	69.6	NT	26.4	99.4	71.8
NA	2013–2016	4687	76.9	NT	24.9	99.6	79.0
EUR	1997–2000	1593	83.8	67.9	33.8	98.8	96.6
EUR	2001–2004	2196	78.7	74.1	40.1	99.9	96.1
EUR	2005–2008	4759	67.4	74.5	43.9	99.8	90.6
EUR	2009–2012	4144	64.8	NT	38.2	99.7	87.7
EUR	2013–2016	3362	64.7	NT	33.1	99.7	90.1
LATAM	1997–2000	491	95.5	69.0	34.2	95.7	98.4
LATAM	2001–2004	560	86.2	72.3	31.1	100.0	94.5
LATAM	2005–2008	1825	83.9	73.1	40.1	99.8	88.7
LATAM	2009–2012	1326	80.2	NT	41.6	99.9	87.3
LATAM	2013–2016	553	78.1	NT	43.8	99.6	83.5
APAC	1997–2000	528	83.0	75.2	33.5	97.0	99.4
APAC	2001–2004	590	73.1	75.6	36.4	100	96.3
APAC	2005–2008	952	66.4	NT	37.2	99.6	86.2
APAC	2009–2012	988	67.9	NT	33.4	99.5	87.0
APAC	2013–2016	418	65.8	NT	33.7	99.5	86.4

Abbreviations: AMP, ampicillin; APAC, Asia-Pacific region; CHL, chloramphenicol; EUR, Europe; LATAM, Latin America; LZD, linezolid; NA, North America; NT, not tested; TET, tetracycline; VAN, vancomycin.

^aCriteria as published by Clinical and Laboratory Standards Institute 2018 [44].

^bThe results of ampicillin susceptibility tests may be used to predict susceptibility to amoxicillin-clavulanate, ampicillin-sulbactam, and piperacillin-tazobactam among non-β-lactamase- producing enterococci and imipenem for E. faecalis [44].

^cChloramphenicol was tested against isolates collected during 1997–2005.

^dOrganisms that are susceptible to tetracycline are also considered susceptible to doxycycline and minocycline. However, some organisms that are intermediate or resistant to tetracycline may be susceptible to doxycycline, minocycline, or both [44].